Lisdexamfetamine Dimesylate Capsule
Product Images NDC 42858-165

Product Visual Gallery

This gallery contains 16 technical images submitted to the FDA as part of the official labeling for Lisdexamfetamine Dimesylate (NDC 42858-165). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Rhodes Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Lisdexcaps 01)

Chemical structure of lisdexamfetamine dimesylate is shown, representing the molecular formula with amine, phenyl, and dimesylate functional groups.*

FDA Label Image

Figure 1 (Lisdexcaps 02)

A chart showing fold changes and 90% confidence intervals for pharmacokinetic parameters Cmax and AUC across special populations. The variables include gender, age groups (65-74 years and 75+ years), and levels of renal impairment (mild, moderate, severe) plus end-stage renal disease, with changes relative to a reference value plotted on the x-axis.*

FDA Label Image

Figure 2 (Lisdexcaps 03)

A chart showing fold change and 90% confidence intervals in pharmacokinetic parameters Cmax and AUC due to interaction with Guanfacine, Venlafaxine, and Omeprazole. The x-axis represents change relative to reference, ranging from 0.0 to 2.0. Data points are plotted for each drug and parameter, comparing changes around a reference value of 1.0.*

FDA Label Image

Figure 3 (Lisdexcaps 04)

A forest plot chart illustrating the fold change and 90% confidence intervals of pharmacokinetic parameters (Cmax and AUC) for various interacting drugs including Guanfacine, Venlafaxine, and several CYP substrates such as Caffeine, Dextromethorphan, Omeprazole, and Midazolam, relative to a reference.*

FDA Label Image

Figure 4 (Lisdexcaps 05)

A line graph comparing LS Mean SKAMP Deportment Scores over time post-dose (hours) between placebo and lisdexamfetamine. The x-axis shows time in hours from 0 to 13, and the y-axis shows scores ranging approximately from 0.0 to 2.0, with error bars. The placebo group shows higher scores overall than the lisdexamfetamine group at most time points.*

FDA Label Image

Figure 5 (Lisdexcaps 06)

A line chart comparing the proportion of subjects with relapse or treatment failure over time (days after randomization) between Lisdexamfetamine and placebo groups. The x-axis represents time in days up to 55 days, and the y-axis shows the percentage of subjects with relapse or treatment failure, ranging from 0% to 100%. The Lisdexamfetamine group shows a lower proportion throughout compared to the placebo group, which rises sharply.*

FDA Label Image

Figure 6 (Lisdexcaps 07)

A line graph comparing LS Mean (SE) PERMP Total Scores over time post-dose (hours) between Lisdexamfetamine and Placebo. The x-axis shows time post-dose from -0.5 to 14 hours, and the y-axis shows PERMP scores from 250 to 330. Lisdexamfetamine data is represented by a solid line with square markers, and Placebo by a dashed line with circle markers, showing higher scores for Lisdexamfetamine at most time points.*

FDA Label Image

Figure 7 (Lisdexcaps 08)

A line graph comparing the proportion of subjects with relapse or treatment failure over time (days after randomization) between Lisdexamfetamine and placebo groups. The x-axis shows days from 0 to 40, and the y-axis shows the proportion of subjects from 0% to 100%. Two curves are depicted: a solid line for Lisdexamfetamine with a low and stable proportion, and a dashed line for placebo showing a steadily increasing proportion of relapse or treatment failure.*

FDA Label Image

Figure 8 (Lisdexcaps 09)

A line graph comparing the proportion of subjects with relapse over time between Lisdexamfetamine and Placebo groups. The x-axis represents time in days after randomization (0 to 209 days), and the y-axis shows the percentage of subjects with relapse (0% to 100%). Two lines are plotted: a solid line for Lisdexamfetamine and a dashed line for Placebo, with subject counts at risk listed below the x-axis for each group over time.*

FDA Label Image

Principal Display Panel (10 mg Capsule Bottle Label)

Label for Lisdexamfetamine Dimesylate Capsules 10 mg by Rhodes Pharmaceuticals LLC. The label indicates the product is prescription only and contains 100 capsules. It provides storage instructions and pharmacist dispensing guidance alongside the NDC 42858-161-01 and a barcode.*

FDA Label Image

Principal Display Panel (20 mg Capsule Bottle Label)

Lisdexamfetamine Dimesylate Capsules 20 mg label from Rhodes Pharmaceuticals LLC. The capsule bottle label includes the proprietary and generic name, dosage strength, quantity of 100 capsules, and storage instructions. It also states pharmacist dispensing instructions and the NDC 42858-162-01 barcode.*

FDA Label Image

Principal Display Panel (30 mg Capsule Bottle Label)

Lisdexamfetamine Dimesylate Capsules 30 mg in a bottle label format by Rhodes Pharmaceuticals LLC. The label includes the NDC number 42858-163-01 and states the package contains 100 capsules. It instructs pharmacists to dispense the accompanying Medication Guide to patients and provides storage conditions and manufacturing information.*

FDA Label Image

Principal Display Panel (40 mg Capsule Bottle Label)

Label for Lisdexamfetamine Dimesylate Capsules 40 mg by Rhodes Pharmaceuticals LLC. The label shows a 100 capsule count container with prescription-only designation. Storage instructions are included, along with a barcode and NDC 42858-164-01.*

FDA Label Image

Principal Display Panel (50 mg Capsule Bottle Label)

Lisdexamfetamine Dimesylate Capsules 50 mg oral dosage form by Rhodes Pharmaceuticals LLC. The label shows the product name, strength, and capsule dosage form with a quantity of 100 capsules. It includes instructions for pharmacists to dispense a medication guide and storage conditions.*

FDA Label Image

Principal Display Panel (60 mg Capsule Bottle Label)

Lisdexamfetamine Dimesylate 60 mg Capsules label for oral use, containing 100 capsules. The label includes prescribing and storage instructions, a caution for pharmacists to dispense a Medication Guide with each prescription, and the labeler information indicating Rhodes Pharmaceuticals LLC. The packaging features a purple and white design with barcode and NDC 42858-166-01.*

FDA Label Image

Principal Display Panel (70 mg Capsule Bottle Label)

Lisdexamfetamine Dimesylate Capsules 70 mg oral capsule label from Rhodes Pharmaceuticals LLC. The label indicates the product name, strength, and quantity of 100 capsules. It includes storage instructions, a barcode, and a note for pharmacists to dispense the accompanying medication guide for each patient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.